High Hematocrit on TRT: Why It Happens and How to Lower It

If you started testosterone replacement therapy (TRT) and your latest blood panel flagged a high hematocrit, you're looking at the single most common lab abnormality the treatment causes. It's not a fluke, and it's not a sign you did anything wrong. Testosterone tells your body to make more red blood cells. That's part of how it works. But left unwatched, a hematocrit that climbs too high can thicken your blood and raise your risk of clots. The good news: it's predictable, trackable, and almost always manageable without quitting TRT.

This guide breaks down why TRT raises your red blood cell count, what numbers actually matter, when to worry, and the practical steps that bring hematocrit back down.

Medical disclaimer: This article is for general education only. It is not medical advice and does not replace your prescriber. Don't start, stop, or change your TRT dose, donate blood, or get a phlebotomy based on what you read here. Talk to the licensed clinician managing your therapy. If you have chest pain, shortness of breath, leg swelling, or signs of a stroke, call emergency services now.

Quick Answer

• Why it happens: Testosterone boosts erythropoietin (EPO) and suppresses a hormone called hepcidin, which frees up iron. Together these push your bone marrow to make more red blood cells, raising hemoglobin and hematocrit (Bachman, 2010; Bachman, 2014).
• When it's a problem: Most clinicians act when hematocrit reaches 52–54%. The Endocrine Society advises evaluating therapy and stopping testosterone until hematocrit drops below 54%, then restarting at a lower dose (Bhasin, 2018).
• Why it matters: Men on TRT who develop polycythemia (hematocrit ≥52%) had a higher rate of heart attack, stroke, and clots in their first year — 5.15% vs 3.87% (Ory, 2022).
• How to lower it: Lower or split your dose, switch from injections to a gel, drop nicotine, stay hydrated, and — when needed — donate blood or get a therapeutic phlebotomy. Injections raise hematocrit far more than gels do.

What Is Hematocrit, and Why Does TRT Raise It?

Hematocrit is the percentage of your blood made up of red blood cells. If your hematocrit is 45%, then 45% of your blood volume is red cells and the rest is plasma and other components. Hemoglobin, the oxygen-carrying protein inside those cells, rises and falls alongside it. The two numbers move together, so when a doctor talks about your "blood getting thick" on TRT, they usually mean both.

A normal hematocrit for adult men runs roughly 41% to 50%. When it climbs above the normal range because of too many red blood cells, that's called erythrocytosis. When the cause is something outside the bone marrow itself — like a drug or low oxygen — doctors call it secondary erythrocytosis or secondary polycythemia. TRT-driven high hematocrit is a textbook example.

Here's why testosterone does it. The hormone acts on red blood cell production through at least two clear pathways:

1. It raises erythropoietin (EPO). EPO is the signal your kidneys send to tell bone marrow to crank out red cells. Testosterone bumps EPO up and resets the "set point" — the level your body treats as normal — so your marrow keeps producing at a higher rate (Bachman, 2014).
2. It suppresses hepcidin. Hepcidin is the master switch that controls how much iron your body releases. Testosterone turns it down, which floods more iron into circulation. More available iron means more raw material for building red blood cells (Bachman, 2010).

There are likely other contributors — direct effects on red cell precursors and slightly longer red cell survival — but EPO and hepcidin are the heavy hitters. The takeaway: a rising hematocrit isn't a side effect that's gone wrong. It's the expected result of a hormone doing exactly what it does. The job is to keep it in a safe lane.

Fast Facts: Hematocrit on TRT

What Hematocrit Level Is Too High on TRT?

This is where the numbers matter, and where guidelines mostly agree. American practice centers on a hematocrit of 54% as the line that demands action, with active management often starting earlier, around 52%.

The Endocrine Society Clinical Practice Guideline is the most cited reference. It recommends measuring hematocrit before starting TRT, again at 3 to 6 months, and then yearly. If hematocrit rises above 54%, the guideline says to stop testosterone, evaluate the patient for hypoxia and sleep apnea, and restart at a reduced dose once levels come back down (Bhasin, 2018). It also advises against starting TRT at all in a man whose baseline hematocrit is already above 48–50%.

The American Urological Association (AUA) guideline likewise tells clinicians to check hemoglobin and hematocrit at baseline and counsel patients about the polycythemia risk before they ever start treatment (AUA Testosterone Deficiency Guideline). FDA testosterone product labels carry a warning that the drugs can increase red blood cell counts and call for periodic hematocrit checks.

Worth knowing: European guidance is often a touch more conservative, contraindicating testosterone above a hematocrit of 54% but flagging the 50–54% zone as a gray area where individual judgment applies. The thresholds aren't magic cutoffs — they're guardrails. Your own baseline, symptoms, and other risk factors all feed into where your prescriber draws the line.

Hematocrit Thresholds: What Happens at Each Level

How Dangerous Is High Hematocrit on TRT?

The concern with a high hematocrit is simple to picture. More red blood cells make blood thicker and more viscous. Thicker blood moves more sluggishly and is more prone to clotting. Clots are what cause heart attacks, strokes, deep vein thrombosis (DVT), and pulmonary embolism. So the worry isn't the number on the lab report — it's the clot the number predicts.

The most pointed evidence comes from a 2022 study in the Journal of Urology. Researchers pulled a database of millions of patients and compared men on TRT who developed secondary polycythemia (hematocrit ≥52%) against men on TRT whose hematocrit stayed normal. In the first year of therapy, the polycythemia group had a higher rate of major adverse cardiovascular events and venous thromboembolism: 5.15% versus 3.87% (Ory, 2022). That's a real, measurable jump tied directly to the elevated hematocrit.

That said, the full picture has nuance. The large TRAVERSE trial — the biggest randomized study of TRT safety, with 5,246 men using a daily testosterone gel — did not find an overall increase in major cardiac events versus placebo, and very few men on the gel crossed the 54% hematocrit threshold (TRAVERSE, NEJM 2023). The contrast with the Journal of Urology data points to two things: the formulation you use matters a lot, and keeping hematocrit controlled is the whole game.

One more wrinkle worth flagging. A 2024 review in Endocrine Connections questioned whether routine phlebotomy is always the right answer, noting that draining blood lowers tissue oxygen and depletes iron in ways that may, in theory, nudge clotting risk in the wrong direction. The authors call for shared decision-making rather than reflexive bloodletting (Bond, 2024). Translation: don't self-prescribe phlebotomy. Work the problem with your doctor.

Which TRT Methods Raise Hematocrit the Most?

If there's one practical lever that changes everything, it's how you take your testosterone. Not all delivery methods hit your red blood cells equally. Injectables are the worst offenders; gels are the gentlest. This is one of the clearest patterns in the entire TRT literature.

The reason is the blood-level rollercoaster. A testosterone injection — especially a larger dose given less often — sends your levels spiking to a high peak, then sliding down to a trough before the next shot. Those supraphysiologic peaks are what hammer your bone marrow into overdrive. Gels deliver a steadier, lower daily level, so the stimulus to make red cells is milder and more constant.

The trial data make the gap stark. In the gel-based TRAVERSE trial, well under 1% of men exceeded a 54% hematocrit (TRAVERSE, 2023). In the T4DM trial, which used long-acting intramuscular testosterone undecanoate, hematocrit rose to 54% or higher in 22% of treated men, and 5% had to stop the study because of it (T4DM, Lancet Diabetes Endocrinol 2021). Same drug class, wildly different erythrocytosis rates — driven mostly by formulation and the testosterone peaks each one produces.

TRT Delivery Methods and Hematocrit Risk

If you want a deeper breakdown of how each option works, dosing, and trade-offs, see our guide on TRT delivery methods: injections vs cream vs pellets vs nasal.

How Do You Lower High Hematocrit on TRT?

Here's the part you came for. A high hematocrit rarely means you have to quit TRT. It means you and your prescriber tune the protocol and, if needed, remove some blood. There's a ladder of options, and most men get back in range with the first few rungs. Work top to bottom, always with your doctor.

1. Lower the dose. The simplest fix. Less testosterone means a smaller signal to your bone marrow. Many men find a modest dose cut drops hematocrit a few points while still controlling symptoms. The Endocrine Society guideline explicitly calls for restarting at a reduced dose after hematocrit normalizes (Bhasin, 2018).

2. Split the dose / inject more often. If you take a large injection once a week or every two weeks, ask about smaller doses given more frequently — say, twice weekly or every other day subcutaneously. Same total testosterone, smaller peaks. Flattening the spikes is one of the most effective ways to tame hematocrit without losing benefit.

3. Switch formulations. Moving from injections to a daily transdermal gel is one of the most reliable ways to bring red cell production down, because gels avoid the peaks entirely (Okano, 2025 systematic review). This is a bigger change, so weigh it with your provider.

4. Fix the multipliers. Smoking and nicotine, untreated sleep apnea, dehydration, and living at high altitude all raise hematocrit on their own and stack on top of TRT. Quitting nicotine and treating sleep apnea can pull your numbers down meaningfully. Staying well hydrated keeps your plasma volume up, which keeps the hematocrit percentage from looking artificially high.

5. Donate blood. Regular blood donation removes red cells and is a legitimate, low-cost way to manage a creeping hematocrit. Many men on TRT donate every two to three months. Note: blood centers have their own eligibility rules, and a hematocrit that's too high may actually disqualify you from donating, which is why this works best as prevention rather than rescue.

6. Therapeutic phlebotomy. When hematocrit is genuinely high (often ≥54%) or you can't donate, a clinician can order a therapeutic phlebotomy — a medical blood draw done specifically to lower red cell mass. It works fast. But as the 2024 review noted, it's not free of downsides; repeated draws deplete iron and can set up a frustrating cycle, so it should be targeted, not routine (Bond, 2024). A broader systematic review in Blood Advances (2025) likewise found that managing drug-induced erythrocytosis usually combines dose changes with selective phlebotomy (Blood Advances, 2025).

Ways to Lower Hematocrit, Ranked by Effort

How Often Should You Check Hematocrit on TRT?

Monitoring is the safety net that makes everything else work, because you cannot feel a rising hematocrit. There are no symptoms until it's high enough to cause trouble. The only way to catch it early is a scheduled blood test.

The standard schedule, drawn from the Endocrine Society guideline, looks like this: check hematocrit before starting, again at 3 to 6 months, and then once a year if it stays stable (Bhasin, 2018). If your numbers run high or you change your dose, your prescriber will check more often — often every few months until things settle.

Don't skip the baseline draw. A pre-treatment hematocrit tells your doctor where you started, which is the only way to judge how far TRT has moved you. For the full lab panel and timing — testosterone, estradiol, PSA, and the rest — see our TRT blood work and monitoring schedule. Hematocrit is also one of the side effects and safety issues every man on therapy should understand before starting.

TRT Hematocrit Monitoring Schedule

Frequently Asked Questions

Does a high hematocrit mean I have to stop TRT forever? Almost never. A high hematocrit usually means your protocol needs adjusting — a lower or split dose, a switch to gel, or blood removal. The Endocrine Society guideline describes pausing testosterone only until levels fall below 54%, then restarting at a reduced dose (Bhasin, 2018). Permanent discontinuation is rare and reserved for men who can't keep hematocrit controlled by any means.

Will drinking more water lower my hematocrit? A little, and it helps your reading be accurate. Dehydration concentrates your blood and makes hematocrit look higher than it really is, so showing up to a blood draw dehydrated can falsely inflate the number. Good hydration won't fix true erythrocytosis on its own, but it keeps your labs honest and supports the other steps.

Is donating blood the same as a therapeutic phlebotomy? They both remove red cells, but they're not identical. Blood donation is voluntary and goes to the blood supply, with eligibility rules set by the blood center — and a hematocrit that's too high can disqualify you. A therapeutic phlebotomy is a medical procedure ordered by your doctor specifically to lower your red cell mass, and it can be done even when you don't qualify to donate.

Why do my injections raise hematocrit more than gels would? Injections, especially larger doses given less often, spike your testosterone to a high peak before dropping to a trough. Those peaks drive your bone marrow hardest. Gels deliver a steady, lower daily level. In trials, fewer than 1% of gel users crossed a 54% hematocrit, versus 22% on long-acting injectable testosterone (TRAVERSE, 2023; T4DM, 2021).

How fast can hematocrit drop once I make changes? It depends on the lever. A phlebotomy or donation lowers it within days. Dose changes and formulation switches work more gradually, over weeks to a couple of months, because your existing red cells live around 120 days and have to cycle out. This is why your doctor usually rechecks 6 to 12 weeks after a change.

Related Reading

• TRT Blood Work: The Labs & Monitoring Schedule
• TRT Side Effects & Safety: What the Evidence Says
• TRT Delivery Methods: Injections vs Cream vs Pellets vs Nasal
• Estrogen Management on TRT (and the Anastrozole Debate)
• Do I Need TRT? Low-Testosterone Symptoms & How It's Diagnosed

Tools and next steps: Compare clinics on our TRT providers directory, weigh your options side by side with our comparison tool, and estimate your monthly spend with the TRT cost calculator.

Sources

1. Bachman E, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010. PMID 20660052
2. Bachman E, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014. PMID 24158761
3. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018. PMID 29562364
4. Ory J, et al. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of MACE and VTE in the First Year of Therapy. J Urol. 2022. PMID 35050717
5. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023. PMID 37326322
6. Wittert G, et al. Testosterone treatment to prevent or revert type 2 diabetes (T4DM). Lancet Diabetes Endocrinol. 2021. PMID 33338415
7. Bond P, et al. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024. PMID 39212549
8. American Urological Association. Testosterone Deficiency Guideline. auanet.org
9. Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review. Blood Advances. 2025. PMID 39913688
10. Okano I, et al. Effect of testosterone formulations on hematocrit in transgender individuals: a systematic review. Andrology. 2025. PMID 39011565